113 related articles for article (PubMed ID: 16533722)
1. Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromes.
Mijovic A; Delforge M; Sekhavat M; Czepulkowski B; Mufti GJ
Haematologica; 2006 Apr; 91(4):572-3. PubMed ID: 16533722
[TBL] [Abstract][Full Text] [Related]
2. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
[TBL] [Abstract][Full Text] [Related]
3. Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors.
Allan DS; Dubé P; Roy J; Busque L; Roy DC
Biol Blood Marrow Transplant; 2007 Apr; 13(4):433-9. PubMed ID: 17382249
[TBL] [Abstract][Full Text] [Related]
4. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
5. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation.
Seshadri T; Al-Farsi K; Stakiw J; Ma C; Saragosa R; Franke N; Keating A; Crump M; Kuruvilla J
Bone Marrow Transplant; 2008 Dec; 42(11):733-7. PubMed ID: 18711349
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
7. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
8. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease.
Gaia S; Smedile A; Omedè P; Olivero A; Sanavio F; Balzola F; Ottobrelli A; Abate ML; Marzano A; Rizzetto M; Tarella C
J Hepatol; 2006 Jul; 45(1):13-9. PubMed ID: 16635534
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
11. Improving stem cell mobilization strategies: future directions.
Bensinger W; DiPersio JF; McCarty JM
Bone Marrow Transplant; 2009 Feb; 43(3):181-95. PubMed ID: 19139734
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
14. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
15. Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.
Majado MJ; Minguela A; González-García C; Salido E; Blanquer M; Funes C; Insausti CL; García-Hernández AM; Moraleda JM; Morales A
J Clin Apher; 2009; 24(1):12-7. PubMed ID: 19170164
[TBL] [Abstract][Full Text] [Related]
16. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients.
Sloand EM; Read EJ; Scheinberg P; Tang Y; More K; Leitman SF; Maciejewski J; Young NS
Transfusion; 2007 Jul; 47(7):1250-3. PubMed ID: 17581160
[TBL] [Abstract][Full Text] [Related]
17. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies.
Bolwell BJ; Pohlman B; Rybicki L; Sobecks R; Dean R; Curtis J; Andresen S; Koo A; Mineff V; Kalaycio M; Sweetenham JW
Bone Marrow Transplant; 2007 Sep; 40(5):437-41. PubMed ID: 17618321
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
20. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
Abraham M; Biyder K; Begin M; Wald H; Weiss ID; Galun E; Nagler A; Peled A
Stem Cells; 2007 Sep; 25(9):2158-66. PubMed ID: 17525235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
